| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)–Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial
|
Fermé, Christophe
|
|
2017
|
81 |
C |
p. 45-55
11 p.
|
artikel
|
| 2 |
A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma – A final report
|
Gnekow, Astrid K.
|
|
2017
|
81 |
C |
p. 206-225
20 p.
|
artikel
|
| 3 |
Attaining precision therapy in prostate cancer: A tall order
|
Efstathiou, Eleni
|
|
2017
|
81 |
C |
p. 226-227
2 p.
|
artikel
|
| 4 |
Breast magnetic resonance imaging use in patients undergoing neoadjuvant chemotherapy is associated with less mastectomies in large ductal cancers but not in lobular cancers
|
Vriens, Ingeborg J.H.
|
|
2017
|
81 |
C |
p. 74-80
7 p.
|
artikel
|
| 5 |
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
|
Emens, Leisha A.
|
|
2017
|
81 |
C |
p. 116-129
14 p.
|
artikel
|
| 6 |
Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm
|
Kwakman, Johannes J.M.
|
|
2017
|
81 |
C |
p. 130-134
5 p.
|
artikel
|
| 7 |
Corrigendum to ‘Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer’ [European Journal of Cancer 76 (2017) 36–44]
|
Massard, Christophe
|
|
2017
|
81 |
C |
p. 242-
1 p.
|
artikel
|
| 8 |
Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis
|
Valachis, Antonis
|
|
2017
|
81 |
C |
p. 106-115
10 p.
|
artikel
|
| 9 |
Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma
|
Penttilä, P.
|
|
2017
|
81 |
C |
p. 9-16
8 p.
|
artikel
|
| 10 |
First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours
|
Rodon, Jordi
|
|
2017
|
81 |
C |
p. 142-150
9 p.
|
artikel
|
| 11 |
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)
|
Carrato, Alfredo
|
|
2017
|
81 |
C |
p. 191-202
12 p.
|
artikel
|
| 12 |
Genetic determinants of response to fibroblast growth factor receptor inhibitors in solid tumours
|
Leroy, Laura
|
|
2017
|
81 |
C |
p. 102-105
4 p.
|
artikel
|
| 13 |
Haematological malignancies following temozolomide treatment for paediatric high-grade glioma
|
Karremann, Michael
|
|
2017
|
81 |
C |
p. 1-8
8 p.
|
artikel
|
| 14 |
Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status
|
Thomsen, Maria
|
|
2017
|
81 |
C |
p. 26-35
10 p.
|
artikel
|
| 15 |
Immune checkpoints inhibitors for solid tumours after allogeneic haematopoietic stem-cell transplantation: About four clinical cases
|
Monneur, Audrey
|
|
2017
|
81 |
C |
p. 138-141
4 p.
|
artikel
|
| 16 |
Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies
|
Bernard-Tessier, Alice
|
|
2017
|
81 |
C |
p. 135-137
3 p.
|
artikel
|
| 17 |
Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: A retrospective multicentre study
|
Yamano, Tomoki
|
|
2017
|
81 |
C |
p. 90-101
12 p.
|
artikel
|
| 18 |
Long-term outcome of cardiac function in a population-based cohort of breast cancer survivors: A cross-sectional study
|
Boerman, Liselotte M.
|
|
2017
|
81 |
C |
p. 56-65
10 p.
|
artikel
|
| 19 |
Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?
|
Verlingue, Loic
|
|
2017
|
81 |
C |
p. 161-173
13 p.
|
artikel
|
| 20 |
Opportunistic autoimmunity secondary to immunotherapy and melanoma: Back to ABCDE?
|
Kostine, Marie
|
|
2017
|
81 |
C |
p. 240-241
2 p.
|
artikel
|
| 21 |
Pembrolizumab-induced Stevens–Johnson syndrome in non-melanoma patients
|
Saw, Stephanie
|
|
2017
|
81 |
C |
p. 237-239
3 p.
|
artikel
|
| 22 |
Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer
|
Armstrong, Andrew J.
|
|
2017
|
81 |
C |
p. 228-236
9 p.
|
artikel
|
| 23 |
Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours
|
Hollebecque, A.
|
|
2017
|
81 |
C |
p. 81-89
9 p.
|
artikel
|
| 24 |
Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial
|
Stahl, Michael
|
|
2017
|
81 |
C |
p. 183-190
8 p.
|
artikel
|
| 25 |
Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma
|
Heppt, Markus V.
|
|
2017
|
81 |
C |
p. 36-44
9 p.
|
artikel
|
| 26 |
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study
|
Chau, Ian
|
|
2017
|
81 |
C |
p. 17-25
9 p.
|
artikel
|
| 27 |
Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review
|
Petrelli, Fausto
|
|
2017
|
81 |
C |
p. 174-182
9 p.
|
artikel
|
| 28 |
Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins
|
Spänkuch, Iris
|
|
2017
|
81 |
C |
p. 203-205
3 p.
|
artikel
|
| 29 |
Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort
|
Pivot, Xavier
|
|
2017
|
81 |
C |
p. 151-160
10 p.
|
artikel
|
| 30 |
What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?
|
Bernabé, Reyes
|
|
2017
|
81 |
C |
p. 66-73
8 p.
|
artikel
|
Tijdschrift beschrijving